Skip to main content
main-content

19-06-2020 | Haematology | Video

EHA25 | First-line inotuzumab ozogamicin plus R-CVP evaluated in anthracycline-unfit DLBCL patients

Elizabeth Phillips describes their phase 2 trial showing that the combination of inotuzumab ozogamicin and R-CVP is efficacious for certain subgroups of treatment-naïve, R-CHOP-ineligible patients with diffuse large B-cell lymphoma, and outlines the next steps to improve treatment outcomes (5:59).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits